Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Colon hypersensitivity to distension, rather than excessive gas production, produces carbohydrate-related symptoms in individuals with irritable bowel syndrome
DESCRIPTION TABLE OF CONTENTS METHODOLOGY DOWNLOAD PDF Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035 USD 72.29 BN MARKET SIZE, 2035 BIOSIMILARS MARKET SIZE, SHARE & GROWTH SNAPSHOT Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis The global biosimilars market is projected to grow from USD 35.04 billion in 2025 to USD 72.29 billion by 2035, at a CAGR of 7.5% during the forecast period
Ongoing Research and Expansion Pharmaceutical companies continue researching new uses for GLP-1 medications, including potential benefits for cardiovascular health and other chronic conditions
Most specialists recommend stopping semaglutide at least 23 months before attempting conception, though some guidelines suggest a shorter washout
At 6 months, 68% had returned to weekly dosing, citing no perceived benefit and increased hassle
Brand names : Mounjaro (for diabetes), Zepbound (for weight loss) Quick Fact : Both medications are injected once weekly and are approved for use in adults with obesity or overweight individuals with at least one weight-related health condition
US$ 28.70
US$ 26.65
US$ 24.05
US$ 25.44
US$ 29.04
US$ 29.11
US$ 20.98
